Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans

Thyroid

Volumn 22, Issue 9, 2012, Pages 877-883

  Sabra, Mona M ^a   Grewal, Ravinder K ^a   Tala, Hernan ^b   Larson, Steve M ^a   Tuttle, R Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Alemana Clinic   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROID HORMONE;

ADULT; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CLINICAL ARTICLE; DISTANT METASTASIS; DOSIMETRY; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROID CARCINOMA; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TREATMENT OUTCOME; WHOLE-BODY COUNTING; YOUNG ADULT;

EID: 84865577953     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0429     Document Type: Article

References (21)

1. Cavalieri RR 1996 Nuclear imaging in management of thyroid carcinoma. Thyroid 6:485-492.
2. Fatourechi V, Hay ID 2000 Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan negative metastasis: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 30:107-114.
3. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW 1994 Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629-634.
4. Duren M, Siperstein AE, Shen W, Duh QY, Morita E, Clark OH 1999 Value of stimulated serum thyroglobulin levels for detecting persistent or recurrent differentiated thyroid cancer in high- and low-risk patients. Surgery 126:13-19.
5. Pacini F, Pinchera A 1990 Serum and tissue thyroglobulin measurement: clinical applications in thyroid disease. Biochimie 81:463-467.
6. Ashcraft MW, Van Herle AJ 1981 The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer Am J Med 71:806-814.
7. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790-1794.
8. Schlumberger M, Mancusi F, Baudin E, Pacini F 1997 131-I therapy for elevated thyroglobulin levels. Thyroid 7:273-276.
9. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, Dullaart RP, Links TP 2003 Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 148:589-596.
10. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488-1492.
11. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM; American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
12. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E,Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097.
13. Kim WG, Ryu JS, Kim EY, Lee JH, Baek JH, Yoon JH, Hong SJ, Kim ES, Kim TY, Kim WB, Shing YK 2010 Empiric highdose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography. J Clin Endocrinol Metab 95:1169-1173.
14. Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK 2003 Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. Clin Endocrinol 58:421-427.
15. Chao M. Management of differentiated thyroid cancer with rising thyroglobulin and negative diagnostic radioiodine whole body scan 2010 Clin Oncol 22:438-447.
16. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88:1107-1111.
17. Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri M 2005 Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest 28:540-546.
18. Biko J, Reiners C, Kreissl MC, Verburg FA, Demidchik Y, Drozd V 2011 Favourable course of disease after incomplete remission on (131)I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years followup. Eur J Nucl Med Mol Imaging 38:651-655.
19. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA 2002 Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 87:1521-1526.
20. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med 45:1366-1372.
21. Van Nostrand D, Khorjekar GR, O'Neil J, Moreau S, Atkins FB, Kharazi P, Mete M, Chennupati SP, Burman KD, Wartofsky L 2012 Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET. J Nucl Med 53:359-362.